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A Ab bs st tr ra ac ct t
Allele-specific expression (ASE) is essential for normal development and many cellular processes
but, if impaired, can result in disease. ASE is a feature of organisms with genomes consisting of
more than one set of homologous chromosomes. The higher the number of chromosome sets
(ploidy) per cell, the higher the potential complexity of ASE. Humans, for instance, are diploid
(except germ cells, which are haploid), resulting in multiple possible expression states in time and
space for each set of alleles. ASE is invoked and modulated by both genetic and epigenetic
changes, affecting the underlying DNA sequence or chromatin of each allele, respectively.
Although numerous methods have been developed to assay ASE, they usually require RNA to be
available and are dependent upon genetic polymorphisms (such as single nucleotide poly-
morphisms (SNPs)) to differentiate between allelic transcripts. The rapid convergence to second-
generation sequencing as the method of choice to examine genomic, epigenomic and
transcriptomic data enables an integrated and more general approach to define and predict ASE,
independent of SNPs. This ‘Omni-Seq’ approach has the potential to advance our understanding
of the biology and pathophysiology of ASE-mediated processes by elucidating subtle combina-
torial effects, leading to the accurate delineation of sub-phenotypes with consequential benefit for
improved insight into disease etiology.
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A Al ll le el le e- -s sp pe ec ci if fi ic c   e ex xp pr re es ss si io on n
The interrelationship between the haploid fractions of
diploid (or polyploid) genomes and how they control a co-
ordinated regulation of gene expression is still poorly
understood. This is despite the fact that the contribution of
expression variation to phenotypic diversity, adaptive
evolution and disease susceptibility is well recognized [1]. It
has been challenging, however, to identify the underlying
mechanisms. For instance, only a small minority of single
nucleotide polymorphisms (SNPs) identified from the recent
plethora of genome-wide disease association studies involved
protein-coding sequence changes. Most of the disease-
associated SNPs were found within non-coding intronic or
intergenic regions from where they are thought to operate on
gene expression through cis-acting mechanisms [2].
Here, we will only consider diploidy, which is the situation
found in all nucleated, somatic cells in humans, giving rise to
five possible expression states for each set of alleles
(Table 1). Expression states 1 and 2 refer to the situations
where expression is either ‘on’ or ‘off’ for both alleles and,
therefore, do not result in allele-specific expression (ASE).
Expression states 3 and 4 refer to the extreme ends of the
ASE spectrum, leading to monoallelic expression caused by
different mechanisms. The first of these is autosomalimprinting: this is a parent-of-origin specific action, where
either the paternal or maternal allele has complete
expression output, either within the entire body, specific
tissue/cell types, specific developmental stages or only for a
particular isoform [3]. Computational prediction suggests
that our current knowledge of imprinted genes is an under-
estimate [4]. A second mechanism is X-inactivation, the
random assignment and maintenance of a clonal lineage,
whereby functional hemizygosity of the homogametic female
genome is invoked for dosage critical genes on one X
chromosome [5]. The third is an as yet unknown mecha-
nism, resulting in wide-spread monoallelic expression of
autosomal genes [6]. This involves the apparently stochastic
choice of either allele to be expressed and was first recog-
nized in a subset of immune and neurological genes,
including those encoding odorant, T cell, and natural killer
cell receptors, as well as immunoglobulin and interleukin
genes. In a subsequent study, almost 10% of the 3,939 genes
assessed were found to have one allele switched off [6]. In
these cases, and contrary to X–inactivation, ASE was not
stable within a clone lineage, as the allele that was expressed
could alternate, and the choice of expression was made
independently for each gene, not for a chromosome in its
entirety. Although genes of diverse functions were involved,
those encoding cell-surface proteins were over-represented,
as well as those undergoing lineage-specific accelerated
evolution. Due to the small sample size, however, some of
these genes may in fact display differential rather than
monoallelic expression [7].
Finally, expression state 5 refers to differential expression
between the two alleles (ASE∆), which, arguably, is the most
common ASE state and is discussed in more detail in the
next section.
M Me et th ho od ds s   f fo or r   t th he e   i id de en nt ti if fi ic ca at ti io on n   o of f   a al ll le el le e- -s sp pe ec ci if fi ic c
e ex xp pr re es ss si io on n
Although the monoallelic mechanism of imprinting was first
identified in 1984 [8], quantitative variance in expression of
the two different alleles was only first acknowledged in
2002, in a small study where 6 of only 13 genes investigated
showed allelic differences [9]. Since these early studies drew
attention to possible cis-regulatory effects causing ASE,
additional individual loci were queried by PCR-based
methods, such as real-time quantitative PCR or discrimi-
nation of PCR products by differing primer extension [10].
However, in order to identify and characterize this variation
on a more genome-wide level, PCR techniques were coupled
with microarray technology. Initially performed by Lo et al.
[11] using an early Affymetrix HuSNP array with approxi-
mately 1,000 exonic SNPs in 602 genes, a surprisingly high
estimate of >50% of genes showed some ASE pattern and
the majority of these were not known to be imprinted.
Thereafter, many further studies have used this approach
dependent upon heterozygous SNPs residing within the
gene’s coding region and, subsequently, compared ratios of
copy DNA (cDNA) from RNA to quantify differences [12,13].
The direct measurement of both alleles within the same
system removes the possible confounding influence of trans-
acting environmental factors. This can identify plausible
imprinted genes, which familial studies can verify. However,
they may also be developmental-, time- or tissue-specific
[13] or display ASE that will show co-segregation through a
pedigree.
Two widely used commercially developed techniques for
ASE analysis include the BeadArray platform and the Oligo
Pool All (OPA) method (Illumina Inc.). In the BeadArray
method, genomic and converted RNA are assessed for the
ratio of each allele by primer extension assays with fluores-
cence-labeled allele-specific primers. The resolution allows a
1.5-fold ASE change to be detected robustly from experi-
mental noise. This method was used by Serre et al. to
estimate that approximately 20% of human genes display
ASE [14]. The OPA method is based on the Golden Gate
assay [15]. By excluding any SNP within within 45 base pairs
(bp) of the start or end of exons, in order to ensure that there
was an equivalent chance of working between genomic DNA
and converted DNA, this method was used to investigate the
unrelated 210 individuals within the HapMap population
[16]. By exploring the interaction between non-synonymous
SNPs and cis-regulatory features, this study estimated ASE
to be approximately 18%.
The major issues with these aforementioned techniques are
threefold, and various adaptations have been developed to
overcome them. Firstly, the influence of bias in PCR
amplification in these ASE examinations has been acknow-
ledged and a custom ASE array has been developed that
removes this possible confounding factor [17]. Secondly,
issues of cross-hybridization were also reduced in the
custom ASE array study by the use of longer probes (39 to
49 bp) and a new probe design. The use of shorter probes
may have also contributed to a possible overestimation of
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Expression states
Non-ASE ASEi/xi ASE∆
Allele 1 2 3 4 5
A On Off On Off ∆
a On Off Off On ∆
Expression states 1 and 2 refer to alleles that do not display allele-specific
expression (ASE). Expression states 3 and 4 refer to alleles that do display
ASE, for example, due to imprinting (ASEi) and X-inactivation (ASExi).
Expression state 5 refers to alleles that display differential ASE (ASE∆),
due to currently unknown mechanism(s).ASE in earlier studies. Probes were designed for the
mismatch base to have a balanced Tm on either side, thus
placing it at the most thermodynamically disruptive
location. Thirdly, the necessity of a SNP to reside within the
transcript limits the number of genes for which there are
informative haplotypes. However, when multiple SNPs
occur, robust results can be elucidated with consistent ratio
differences, which is considerably aided if these SNPs are in
strong linkage disequilibrium (LD) with each other. Verlaan
et al. [18] have modified their method to investigate un-
spliced primary transcripts, thereby including the intronic
regions and thus greatly increasing the number of
polymorphisms that can be used to delineate allele calls.
These results estimated that >10% of genes expressed in a
lymphoblastoid cell line exhibited ASE. An alternative
approach, independent of the transcription of coding region
SNPs, is to use a marker of transcriptional activity (such as
phosphorylated RNA polymerase II (Pol II)), as developed in
the haploChIP method [19]. By immunoprecipitation of
phosphorylated Pol II cross-linked to chromatin, the relative
DNA fragment amounts of these protein-DNA interactions
are differentiated by the use of any SNP within the location
of interest.
E Ep pi ig ge en ne et ti ic ca al ll ly y   d dr ri iv ve en n   a al ll le el le e- -s sp pe ec ci if fi ic c   e ex xp pr re es ss si io on n
The significant role of DNA methylation as a common
driving factor in ASE has been substantiated by a number of
studies, including a recent investigation of a cohort of
pediatric patients with acute lymphoblastic leukaemia. In
this study, DNA and RNA from both blood and bone marrow
were analyzed and 16% were found to display ASE [7]. A
direct quantitative correlation between ASE and CpG site
methylation was observed within individual samples. The
unequal epigenetic state of each haploid genome is clearly a
major factor in the asymmetrical expression of the two
alleles. Genome-wide methods to investigate the epigenome,
including DNA methylation with methylated DNA immuno-
precipitation (MeDIP) [20] and chromatin structure with
chromatin-dependent immunoprecipitation (ChIP) [21] have
enabled a primary view of these features.
The concept of specific epigenetic haplotypes or ‘hepitypes’
that may add additional power to phenotype-related studies
was proposed by Murrell et al. [22] and initial support for
this concept has come from the work of Kerkel et al. [23].
Although allele-specific methylation of CpG dinucleotides is
a characteristic feature of imprinted loci, a genomic exami-
nation by methylation-sensitive restriction enzymes and
subsequent analysis on microarray revealed regions where
adjacent SNPs were influential [23]. The sequence, as
opposed to parental origin (as would be expected in im-
printed loci), was associated with methylation state in a
dozen regions. Thus, a comparison of common haplotypes
within linkage disequilibrium blocks of disease-association
SNPs for their methylation status may well reveal whether
the epigenetic state of these hepitypes links SNPs with
expression and possible phenotype and/or disease suscep-
tibility. However, the necessity for functional examination of
cis-regulation in the appropriate tissue has also been
highlighted by the observation that in approximately 50% of
differing tissues the same haplotype has differing effects
[18]. Furthermore, Zhang et al. [24] found that while DNA
methylation levels were usually very comparable in different
cells, ASE was not, reinforcing the possibility of environ-
ment-specific hepitype interactions.
I In nt te eg gr ra at te ed d   a ap pp pr ro oa ac ch h   f fo or r   t th he e   i id de en nt ti if fi ic ca at ti io on n   o of f   a al ll le el le e- -
s sp pe ec ci if fi ic c   e ex xp pr re es ss si io on n
The recent combination and integration of more than one
method of investigation has opened a novel route into ASE-
related research [25]. Exploring the discriminatory power of
different epigenetic states, Wen et al. [25] investigated if
ASE (and imprinting) could be analyzed independently of
SNPs. For that, they assayed the two parentally derived
genomes for DNA methylation using MeDIP and the histone
methylation mark H3 lysine-4 dimethylation (H3K4Me2)
using ChIP. While DNA methylation (particularly at promo-
ters) is associated with heterochromatic and transcrip-
tionally inactive regions, the presence of H3K4Me2 is
associated with euchromatic and actively transcribed regions
of the genome. The authors hypothesized that the regions
where DNA methylation and H3K4Me2 co-localized (‘double
hits’) should be enriched for ASE due to imprinting (ASEi) if
the two marks were to map to separate parental chromo-
somes. Using custom tiling arrays enriched for imprinted
and non-imprinted genes, respectively, they found that
imprinted genes were enriched (more than fivefold) for
‘double hits’, which were frequently located at transcrip-
tional start sites near antisense or alternative transcripts. If a
third mark, CTCF binding sites (an insulator protein often
associated with imprinted genes [26]), was assayed as well,
known imprinted genes were enriched (>75-fold) by ‘triple
hits’. As expected, the ‘double hits’ (DNA methylation and
H3K4Me2) were mapped to opposite alleles.
The obvious limiting factor of this approach is the depen-
dence upon preselected regions present on the microarrays,
which results in only a small fraction of the genome being
evaluated. The coupling of the immuno-capturing tech-
niques of MeDIP and ChIP with the power of massive
parallel second-generation sequencing for MeDIP-Seq [27]
and ChIP-Seq [28] is swiftly leading to the replacement of
microarrays as the platform of choice for epigenome
analysis, resulting in far improved resolution and coverage.
The revolutionary possibilities of this technique have been
rapidly seized upon with an exponential expansion in whole-
genome investigations, including transcriptome analysis.
Using RNA-Seq [29], all species of RNA transcripts, inclu-
ding coding RNAs and non-coding RNAs, such as
microRNAs, Piwi-interacting RNAs, short interfering RNAs
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single base pair resolution and a wide dynamic range of
expression.
All these different but complementary techniques (MeDIP-
Seq, ChIP-Seq and RNA-Seq) can now be conducted on one
sequencing platform, facilitating a coordinated and
integrated ‘Omni-Seq’ approach for genomic, epigenomic
and expression analyses to be run in parallel. Such
combinatorial analyses have the potential and power to
delineate subtle modifications that may not be detectable by
one technique alone. The challenges for bioinformatics are
obviously daunting, with mammoth amounts of data
currently being generated using just one method. However,
this concern is being tackled and experience tells us that it is
not insurmountable [30]. Looking back, solutions were
eventually found for the exponential growth of data in the
past decade. We predict that such a harmonized approach
will be able to tease out the most informative combinatorial
causes of ASE and will become the integrated method of
biological examination, with as yet unforeseen benefits for
human health prediction, prognostication and diagnosis.
C Co on nc cl lu ud di in ng g   r re em ma ar rk ks s   a an nd d   o ou ut tl lo oo ok k
ASE is clearly a common and highly complex phenomenon.
Simplistically, ASE and ASE∆ in particular, can be invoked
by three cis-acting mechanisms (Figure 1): genetically
driven, for example, via sequence variation; epigenetically
driven, for example, via DNA methylation and/or chromatin
modification; or (epi)genetically driven, for example, via
hepitypes. In addition, there is evidence for as yet unknown
trans-acting mechanisms effecting ASE∆. Emerging techno-
logies such as ‘4C’ [31], which use chromosome confirmation
capture in conjunction with microarrays or second-
generation sequencing platforms, increasingly allow the
ability to assay the three-dimensional nuclear organization
for unbiased interaction of genomic sequences in cis as well
as trans.
There can be little doubt that the advances in ASE discussed
here will translate into clinical benefits in the not too distant
future. In the area of diagnostics, for instance, the
exploitation of ASE is already well underway for tumor type
classification, evaluation of differential gene expressivity or
penetrance in monogenic hereditary conditions and the
discovery of currently unknown imprinted genes with res-
pect to their roles in developmental syndromes. In addition,
ASE can be expected to shed more light on the critical
pathophysiology and epistatic factors in complex diseases.
The exploitation of ASE for therapeutics may take a little
longer, but certainly has tremendous potential, particularly
when coupled with targeted RNA-based therapy [32]. In this
context, ASE may enable the identification of critical
disease-causing haplotypes, epitypes and hepitypes for
down-regulation with targeted RNA interference-based
therapies.
Thus, accurate delineation of an allele’s genetic and
epigenetic state, linked with knowledge of its transcriptional
output, will undoubtedly improve our understanding of ASE
and its wide-ranging implications for genome biology and
medicine.
A Ab bb br re ev vi ia at ti io on ns s
ASE, allele specific expression; bp, base pair; ChIP,
chromatin dependent immunoprecipitation; H3K4Me2, H3
lysine-4 dimethylation; LD, linkage disequilibrium; MeDIP,
methylated DNA immunoprecipitation; OPA, oligo pool all
method; Pol II, RNA polymerase II; SNP, single nucleotide
polymorphism.
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F Fi ig gu ur re e   1 1
Mechanisms capable of invoking differential allele-specific expression
(ASE∆): genetically driven by cis-acting polymorphisms; epigenetically
driven by cis-acting epigenetic effectors; hepitype driven by a combination
of genetic and epigenetic effectors; and driven by as yet unknown trans
effectors.
A
S
E
∆
Allele A
Allele a
Genetic cis effector
Epigenetic cis effector
Unknown trans
effector 
Key:Medical Genomics at University College London and is
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plasticity in health and disease [33]. 
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